Seqanswers Leaderboard Ad

Collapse

Announcement

Collapse
No announcement yet.
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • #16
    Originally posted by AllSeq View Post
    After effectively exiting the NGS market in 2013, Roche is making moves to get back into it with their acquisition of Genia for up to $350M ($125 up front and $225 in potential future payments). Read more on our blog.
    Brilliant move or sign of desperation on the part of Roche? After sending $60M+ down the drain with IBM they are now back to the big dance, now with (apparently) murky IP situation. ONT has licensed so much IP on the biochemistry side that it is not clear (to me) how Genia works around that. Judging from the patents that are now published, the sensors themselves are interesting but not terribly unique. The guys know their analog design (duh), but without biochemistry they will go nowhere. Maybe this is what Roche is banking on - take the platform and add their own biochemistry.

    Comment


    • #17
      Originally posted by BBoy View Post
      The guys know their analog design (duh), but without biochemistry they will go nowhere. Maybe this is what Roche is banking on - take the platform and add their own biochemistry.
      Genia seems to be claiming two advantages:
      1) Precise control over the nanopore assembly process, allowing for 'better than Poisson' distribution

      2) NanoTag biochemistry (being co-developed with Columbia and Harvard)

      Do you not think this biochemistry confers an advantage (or are you saying they don't really 'own' it due to the murky nanopore IP situation)?
      AllSeq - The Sequencing Marketplace
      [email protected]
      www.AllSeq.com

      Comment


      • #18
        Originally posted by AllSeq View Post
        Do you not think this biochemistry confers an advantage (or are you saying they don't really 'own' it due to the murky nanopore IP situation)?
        Their hardware, as much as can be judged from their patents and public presentations is elegant. Murky biochem IP is indeed the right way to characterize things. There are multiple startups, universities, and established companies working in this area, some with overlapping IP claims. It will be interesting to sit back and watch the lawyers get paid large amounts of money to argue about trivialities.

        Comment


        • #19
          Originally posted by scbaker View Post
          Very interesting. Do you know if they've purchased the IP from $LIFE or if they have any commercialization plans?
          I'm curious about this part as well. I wonder if Thermo Fisher dumped any ties with Genia after the Life acquisition?

          Comment


          • #20
            Originally posted by snetmcom View Post
            I'm curious about this part as well. I wonder if Thermo Fisher dumped any ties with Genia after the Life acquisition?
            Still haven't heard anything else about the group working on Starlight.

            As for Thermo, my assumption is they still own a portion Genia and will make a bit of money on their investment once the acquisition closes.
            AllSeq - The Sequencing Marketplace
            [email protected]
            www.AllSeq.com

            Comment

            Latest Articles

            Collapse

            • seqadmin
              Essential Discoveries and Tools in Epitranscriptomics
              by seqadmin


              The field of epigenetics has traditionally concentrated more on DNA and how changes like methylation and phosphorylation of histones impact gene expression and regulation. However, our increased understanding of RNA modifications and their importance in cellular processes has led to a rise in epitranscriptomics research. “Epitranscriptomics brings together the concepts of epigenetics and gene expression,” explained Adrien Leger, PhD, Principal Research Scientist on Modified Bases...
              Yesterday, 07:01 AM
            • seqadmin
              Current Approaches to Protein Sequencing
              by seqadmin


              Proteins are often described as the workhorses of the cell, and identifying their sequences is key to understanding their role in biological processes and disease. Currently, the most common technique used to determine protein sequences is mass spectrometry. While still a valuable tool, mass spectrometry faces several limitations and requires a highly experienced scientist familiar with the equipment to operate it. Additionally, other proteomic methods, like affinity assays, are constrained...
              04-04-2024, 04:25 PM

            ad_right_rmr

            Collapse

            News

            Collapse

            Topics Statistics Last Post
            Started by seqadmin, 04-11-2024, 12:08 PM
            0 responses
            39 views
            0 likes
            Last Post seqadmin  
            Started by seqadmin, 04-10-2024, 10:19 PM
            0 responses
            41 views
            0 likes
            Last Post seqadmin  
            Started by seqadmin, 04-10-2024, 09:21 AM
            0 responses
            35 views
            0 likes
            Last Post seqadmin  
            Started by seqadmin, 04-04-2024, 09:00 AM
            0 responses
            55 views
            0 likes
            Last Post seqadmin  
            Working...
            X